Please provide your email address to receive an email when new articles are posted on . The average health care cost per patient in the indwelling pleural catheter (IPC) group was $40,179 vs. $46,640 ...
(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...
Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for advanced ...
Surgery for malignant pleural mesothelioma after radiotherapy may increase overall survival rates, according to a study. However, study authors note that the procedure should only be adopted in ...
Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations. If you have the appropriate software installed, you can download article citation data ...
ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in ...
Future Oncol. 2009;5(3):391-402. 1 Laboratory of Molecular Oncology, Clinic and Policlinic of Oncology, University Hosptial, CH-8091 Zürich, Switzerland. 2 Division of Thoracic Surgery, University ...
A study of 2,804 patients with stage I to stage III malignant pleural mesothelioma (MPM) found significant variability in access to care and a positive association between multimodality treatment, ...
Researchers at Wake Forest School of Medicine have discovered that a nanoparticle therapeutic enhances cancer immunotherapy and is a possible new approach in treating malignant pleural effusion (MPE).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback